Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker-Reference-Cited by-同舟云学术

Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker

Published:2022-12-16 Issue:1 Volume:161 Page:165-174
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Carlos-Escalante José Alberto^ORCID,Mejía-Pérez Sonia Iliana^ORCID,Soto-Reyes Ernesto^ORCID,Guerra-Calderas Lissania^ORCID,Cacho-Díaz Bernardo^ORCID,Torres-Arciga Karla^ORCID,Montalvo-Casimiro Michel^ORCID,González-Barrios Rodrigo^ORCID,Reynoso-Noverón Nancy^ORCID,Ruiz-de la Cruz Miguel^ORCID,Díaz-Velásquez Clara Estela,Vidal-Millán Silvia^ORCID,Álvarez-Gómez Rosa María^ORCID,Sánchez-Correa Thalía Estefanía^ORCID,Pech-Cervantes Claudio Hiram,Soria-Lucio José Antonio^ORCID,Pérez-Castillo Areli,Salazar Ana María,Arriaga-Canon Cristian^ORCID,Vaca-Paniagua Felipe^ORCID,González-Arenas Aliesha^ORCID,Ostrosky-Wegman Patricia^ORCID,Mohar-Betancourt Alejandro^ORCID,Herrera Luis A.^ORCID,Corona Teresa^ORCID,Wegman-Ostrosky Talia^ORCID

Funder

Consejo Nacional de Ciencia y Tecnología

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11060-022-04214-1.pdf

Reference45 articles.

1. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol 23(12):31–3105. https://doi.org/10.1093/neuonc/noab200

2. Neth B, Carabenciov I, Ruff M, Johnson D (2021) Temporal trends in glioblastoma survival progress then plateau. Neurologist 27(3):119–124. https://doi.org/10.1097/NRL.0000000000000393

3. Dong X, Noorbakhsh A, Hirshman BR et al (2014) Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neuro-Oncol Pract 3(1):29–38. https://doi.org/10.1093/nop/npv016

4. Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331

5. Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170–186. https://doi.org/10.1038/s41571-020-00447-z